Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Placebo-Controlled Study of AGN-151586 for the Treatment of Moderate to Severe Glabellar Lines

NCT06308198 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06308198
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06308198 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Placebo-Controlled Study of AGN-151586 for the Treatment of Moderate to Severe Glabellar Lines
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
March 29, 2024
Completion date
February 26, 2025
Enrollment
161 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

glabellar lines